Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | F7 | P08709 | 4/20 | 0.52 |
| ▸ | F3 | P13726 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | FABP3 | P05413 | 3/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23417025 | 0.96 | FAAH (0.56) | MGLLFAAHALDH1A1KDM4EPPARG | |
| SCHEMBL17780094 | 0.96 | PRKCA (0.49) | MGLLFAAHF7F3PPARG | |
| SCHEMBL5066137 | 0.96 | PRKCA (0.49) | MGLLFAAHF7F3PPARG | |
| SCHEMBL2779347 | 0.96 | PRKCA (0.49) | MGLLFAAHF7F3PPARG | |
| SCHEMBL2779350 | 0.96 | PRKCA (0.49) | MGLLFAAHF7F3PPARG | |
| SCHEMBL18206407 | 0.96 | PRKCA (0.49) | MGLLFAAHF7F3PPARG | |
| SCHEMBL5066142 | 0.96 | PRKCA (0.49) | MGLLFAAHF7F3PPARG | |
| SCHEMBL27409126 | 0.88 | MGLL (0.43) | MGLLFAAHALDH1A1F7F3 | |
| SCHEMBL1361856 | 0.87 | KMT2A (0.54) | LMNA | |
| SCHEMBL18218758 | 0.87 | KMT2A (0.54) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20200384010-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | SHIONOGI & CO., LTD. (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3603648-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | Shionogi & Co., Ltd (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | FABP1, POLRMT, SREBF1 | MGLL 47/4885FAAH 1579/4885ALDH1A1 3124/4885 |
| US-20200384010-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | FABP1, POLRMT, SREBF1 | MGLL 47/4885FAAH 1579/4885ALDH1A1 3124/4885 |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | MGLL 61/4885FAAH 116/4885ALDH1A1 939/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | MGLL 65/4885FAAH 97/4885ALDH1A1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.